0001209191-16-137674.txt : 20160817 0001209191-16-137674.hdr.sgml : 20160817 20160817194535 ACCESSION NUMBER: 0001209191-16-137674 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160815 FILED AS OF DATE: 20160817 DATE AS OF CHANGE: 20160817 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scibetta James S CENTRAL INDEX KEY: 0001383242 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 161839792 MAIL ADDRESS: STREET 1: C/O BIOENVISION, INC. STREET 2: 345 PARK AVENUE, 41ST. FLOOR CITY: NEW YORK STATE: NY ZIP: 10154 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-08-15 0 0001396814 Pacira Pharmaceuticals, Inc. PCRX 0001383242 Scibetta James S C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 President Common Stock 2016-08-15 4 M 0 9123 1.61 A 36207 D Common Stock 2016-08-15 4 M 0 15877 1.61 A 52084 D Common Stock 2016-08-15 4 S 0 25000 45.21 D 27084 D Stock Option (Right to Buy) 1.61 2016-08-15 4 M 0 9123 0.00 D 2020-09-02 Common Stock 9123 0 D Stock Option (Right to Buy) 1.61 2016-08-15 4 M 0 15877 0.00 D 2020-09-02 Common Stock 15877 22373 D The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Includes 330 shares of common stock acquired under the issuer's employee stock purchase plan in June 2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.82 to $45.76, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2. The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering. The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering. /s/ James Scibetta 2016-08-17